3D printing of multidrug tablets for breast cancer
The development and testing of personalised, multidrug tablets will be one of the outputs of a new research collaboration between Gustave Roussy and FabRx Ltd, a biotechnology start-up company. The 3D printed formulations will contain and anticancer agent and drugs to counter its side-effects and will be produced using FabRx’s pharmaceutical 3D printer, M3DIMAKER ™. Once the new formulations have been developed, these drugs will be tested in a multicentre clinical study led by Gustave Roussy to assess the efficacy, acceptability and adherence to treatment compared to conventional care.
3D printing of doses offers the opportunity to personalise doses easily and economically.
Maxime Annereau, pharmacist responsible for this project at Gustave Roussy and Dr Barbara Pistilli, oncologist and Head of the mammary pathology committee at Gustave Roussy said:
“To reduce the risk of recurrence, many women with localised breast cancer are treated with hormone therapy for five years. They often need to take other treatments to manage the side effects. Taking all of these treatments in a single 3D printed tablet with a personalised dosage should improve treatment adherence. This collaboration will allow us to go even further in personalised medicine and to offer our patients a tailor-made medicine” .
This project is part of the INTERLACE program led by Dr Ines Vaz-Luis, oncologist and researcher at Gustave Roussy. This large program, dedicated to patients in remission from breast cancer, aims to transform their care by focusing on the personalisation of care through the development of new therapeutic tools.
